BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 37359551)

  • 1. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
    Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
    Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang T; Wang Y; Shi C; Liu X; Lv S; Wang X; Li W
    Front Pharmacol; 2022; 13():955701. PubMed ID: 36133806
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis.
    Su Q; Zhang XC; Zhang CG; Hou YL; Yao YX; Cao BW
    J Immunol Res; 2018; 2018():1027323. PubMed ID: 29971244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis.
    George J; Bajaj D; Sankaramangalam K; Yoo JW; Joshi NS; Gettinger S; Price C; Farrell JJ
    Pancreatology; 2019 Jun; 19(4):587-594. PubMed ID: 31076344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
    Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials.
    Liu H; Luo SX; Jie J; Peng L; Wang S; Song L
    Front Immunol; 2023; 14():1115305. PubMed ID: 36926326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
    Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
    Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R
    Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.
    Mei T; Wang T; Deng Q; Gong Y
    Front Immunol; 2023; 14():1062679. PubMed ID: 36825025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
    Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
    J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
    Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
    J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
    Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
    Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.